ZyVersa Therapeutics Inc. Cash Flow Conversion Efficiency
ZyVersa Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, ZyVersa Therapeutics Inc. (ZVSA) has a cash flow conversion efficiency ratio of 119.987x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.41 Billion) by net assets ($-11.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ZyVersa Therapeutics Inc. (2020–2024)
Cash flow conversion efficiency of ZyVersa Therapeutics Inc. from 2020 to 2024. This chart illustrates how ZyVersa Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of ZyVersa Therapeutics Inc. for real-time trading data and today's change.
ZyVersa Therapeutics Inc. Cash Flow Conversion Ratio Explained
ZyVersa Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ZyVersa Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZyVersa Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see ZVSA market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mobile-health Network Solutions Class A Ordinary Shares
NASDAQ:MNDR
|
-0.508x |
|
Regent Pacific Properties Inc
V:RPP
|
0.061x |
|
First Tin PLC
LSE:1SN
|
-0.028x |
|
Migo Opportunities Trust PLC
LSE:MIGO
|
-0.009x |
|
GACM Technologies Limited
NSE:GATECHDVR
|
N/A |
|
Colefax Group
LSE:CFX
|
0.297x |
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
0.090x |
|
Ovoca Gold PLC
IR:OVXA
|
-0.136x |
Annual Cash Flow Conversion Efficiency for ZyVersa Therapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of ZyVersa Therapeutics Inc. from 2020 to 2024. Review ZyVersa Therapeutics Inc. free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.52 Million | $-7.56 Million | -0.888x | -12.72% |
| 2023-12-31 | $11.07 Million | $-8.72 Million | -0.787x | -1510.74% |
| 2022-12-31 | $99.99 Million | $-4.89 Million | -0.049x | -112.04% |
| 2021-12-31 | $-12.50 Million | $-5.08 Million | 0.406x | -31.99% |
| 2020-12-31 | $-8.56 Million | $-5.11 Million | 0.597x | -- |
About ZyVersa Therapeutics Inc.
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glome… Read more